image: The engineered bispecific antibody targets p95HER2 (blue fragment), which is unique to malignant breast cancer cells (brown). The antibody can therefore guide T cells (blue cells) to cancer cells without attacking healthy breast epithelial cells (pink). This material relates to a paper that appeared in the Oct. 3, 2018, issue of Science Translational Medicine, published by AAAS. The paper, by I. Rius Ruiz at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain, and colleagues was titled, "p95HER2-T cell bispecific antibody for breast cancer treatment." view more
Credit: Vall d'Hebron Institute of Oncology (VHIO)